Anti-tumor effect of antibody drug conjugate ASP1235 targeting Fms-like tyrosine kinase 3 with venetoclax plus azacitidine in an acute myeloid leukemia xenograft mouse model
Sign Up to like & getrecommendations! Published in 2022 at "Oncotarget"
DOI: 10.18632/oncotarget.28331
Abstract: Antibody drug conjugates (ADC) are one of the attractive modalities for the treatment of acute myeloid leukemia (AML). Previously, we have developed ASP1235, a novel ADC targeting Fms-like tyrosine kinase 3 (FLT3) which is widely… read more here.
Keywords: effect; combination; plus azacitidine; model ... See more keywords